Navigation Links
PharmaNet and Maisonneuve-Rosemont Hospital Collaborate to Evaluate Innovative Drugs
Date:5/25/2011

PRINCETON, N.J., May 25, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that its subsidiary, PharmaNet Canada, Inc. (PharmaNet) and Maisonneuve-Rosemont Hospital (HMR) and its Research Center, one of the largest centers for nephrology in a single location in Canada, have agreed to collaborate in the conduct of pharmacokinetic studies in patients with impaired renal function.  

At PharmaNet's clinical pharmacology unit in Canada, new drugs are evaluated in Phase I clinical studies for PharmaNet's clients. Under the current FDA draft guidance, certain of these studies require the evaluation of drug products in study participants that have impaired renal function. The collaboration with HMR will provide PharmaNet enhanced access to potential study participants with mild, moderate, or severe impaired renal function.  

"We are very pleased to partner with HMR," commented Riaz Bandali, President, Early Stage Development. "Demand for the conduct of pharmacokinetic studies in patients with impaired renal function is increasing. By partnering with HMR, a leading nephrology center and specialized hospital, we can efficiently conduct trials in patients with various levels of renal impairment, while assuring the patients' safety and well-being."

Mr. Bandali added, "We view this partnership with HMR as an important first step in PharmaNet's strategy to expand our academic expertise and the number of first-in-person and patient studies that we conduct in hospital settings."

"By partnering with PharmaNet, our renal impaired patients have the opportunity to contribute to the evaluation of innovative, potentially life-saving therapeutics in a safe environment with their own physicians," commented Dr. Vincent Pichette, Nephrologist-Pharmacologist and Director of the Nephrology Research, Maisonneuve-Rosemont Hospital.

Dr. Pichette added, "PharmaNet's professionalism and commitment to patient safety made them the partner of choice for the hospital. Our experience with them has been very positive."  

About PharmaNet PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com and www.pharmanetclinics.com.

About CRHMRThe Maisonneuve-Rosemont Hospital Research Centre (CRHMR) is responsible for fulfilling the research mandate of the Hospital's mission. To achieve this, the Centre provides research investigators with an environment that is conducive to the advancement of scientific knowledge within the biomedical field. It also facilitates the transfer of technology into clinical practice as well as participates in training new research investigators and evaluating new technology. The Centre oversees the development of leading-edge research in areas that are closely connected to the clinical branches of excellence of the Maisonneuve-Rosemont Hospital: Immunology-oncology, Nephrology, Vision health.  Additional information can be found at http://recherche.maisonneuve-rosemont.org/.

About HMRAffiliated with the University of Montreal, the Maisonneuve-Rosemont Hospital is a great institution where health care, education and medical research converge. Its 5,500 employees and physicians work for the population of greater Montreal and beyond, as the hospital has a supra-regional vocation. Three clinical areas stand out: eye health, hematology-oncology and nephrology.
Each year, the hospital receives more than 4000 students, future doctors, nurses and health professionals. The Maisonneuve-Rosemont Hospital also houses a major research center.

The HMR hosts the second largest program of blood stem cell transplantation in Canada, realizing between 160 to 185 transplants annually. It is also one of the four most respected centers in North America.  In 2008, the transplant program received the (FACT) accreditation, from the Foundation for Accreditation of Cellular Therapy, which certifies the level of quality recognized worldwide with regards to the handling of stem cells and patient care. Recently, the Ministry of Health and Social Services (MHSS) Directorate for the fight against cancer awarded the HMR a level 4, the highest standard of excellence for health plan.Contact Information:Name: Anne-Marie Hess

Name: Francois BrochuPharmaNet Development Group, Inc.

Maisonneuve-Rosemont Hospital Phone: +1 609 951-6842

Phone: 514 252-3451Email: ahess@pharmanet.com

Email: fbrochu.hmr@ssss.gouv.qc.ca
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Experts to Showcase Bioanalytical Posters at ASMS 2011
2. JLL Partners Sells PharmaNet
3. inVentiv Health to Acquire PharmaNet
4. Valerie Palumbo Joins PharmaNet as Senior Vice President, Corporate Quality Assurance
5. PharmaNet Shares Expertise in Drug Development Outsourcing at the 2011 Partnerships in Clinical Trials Conference
6. Dr. Jeffrey Freitag Appointed Chief Medical Officer of PharmaNet
7. PharmaNet and Anapharm Europe Formally End Joint Venture
8. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
9. PharmaNets Technology Investments Translate to Enhanced Client Service in Its Phase I Clinics
10. PharmaNet Launches New Brand Identity at Upcoming Industry Conferences
11. PharmaNet Development Group Announces Observational Research Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):